Proficio Capital Partners LLC Makes New $339,000 Investment in Gilead Sciences, Inc. (NASDAQ:GILD)

Proficio Capital Partners LLC acquired a new position in Gilead Sciences, Inc. (NASDAQ:GILD) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 3,675 shares of the biopharmaceutical company’s stock, valued at approximately $339,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. HHM Wealth Advisors LLC grew its holdings in Gilead Sciences by 118.5% in the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 154 shares during the last quarter. YANKCOM Partnership acquired a new position in Gilead Sciences in the 4th quarter valued at approximately $28,000. Decker Retirement Planning Inc. bought a new stake in shares of Gilead Sciences in the 4th quarter worth approximately $29,000. Crews Bank & Trust acquired a new stake in shares of Gilead Sciences during the 4th quarter worth approximately $31,000. Finally, Stephens Consulting LLC raised its stake in shares of Gilead Sciences by 325.0% in the fourth quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 260 shares in the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total transaction of $228,375.00. Following the sale, the chief financial officer now directly owns 129,873 shares of the company’s stock, valued at $11,863,898.55. The trade was a 1.89 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Insiders sold 302,785 shares of company stock valued at $30,503,250 in the last ninety days. 0.16% of the stock is currently owned by corporate insiders.

Gilead Sciences Stock Up 1.1 %

NASDAQ:GILD opened at $107.89 on Wednesday. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24. The stock has a 50-day moving average price of $104.35 and a two-hundred day moving average price of $94.36. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $119.96. The stock has a market cap of $134.36 billion, a price-to-earnings ratio of 291.59, a PEG ratio of 0.71 and a beta of 0.21.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. As a group, equities analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Friday, March 14th will be paid a $0.79 dividend. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.77. The ex-dividend date is Friday, March 14th. This represents a $3.16 annualized dividend and a yield of 2.93%. Gilead Sciences’s payout ratio is presently 854.05%.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on GILD shares. Deutsche Bank Aktiengesellschaft raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and increased their price target for the stock from $80.00 to $120.00 in a research report on Tuesday, February 18th. DZ Bank upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $108.00 target price for the company in a research report on Thursday, February 13th. The Goldman Sachs Group increased their price target on Gilead Sciences from $85.00 to $96.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 12th. Oppenheimer raised their target price on Gilead Sciences from $115.00 to $132.00 and gave the company an “outperform” rating in a research note on Tuesday, March 4th. Finally, Piper Sandler increased their price objective on shares of Gilead Sciences from $105.00 to $110.00 and gave the stock an “overweight” rating in a report on Wednesday, February 12th. Eleven analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $104.52.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.